Supply Chain Intelligence

Olema Pharmaceuticals, Inc. Supply Chain

OLMA supply chain intelligence for Olema Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

OLMA ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

4Suppliers
16Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

Olema Pharmaceuticals, Inc. (OLMA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships
3Distinct source URLs
7High confidence
0.720Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Olema Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
KR-OYSTER-POINT-II-LLC KR-OYSTER-POINT-II-LLC 92% The Company entered into a lease agreement with KR Oyster Point II, LLC, a Delaware limited liability company (the “Landlord”), pursuant to which the Company will lease an aggregate of approximately …
PFIZER-INC PFIZER-INC 92% Under the terms of the 2025 Pfizer Agreement, we are responsible for conducting the clinical trial for the combined therapies and Pfizer is responsible for supplying atirmociclib to us at no cost.
NOVARTIS-INSTITUTES-FOR-BIOMEDICAL-RESEARCH-INC NOVARTIS-INSTITUTES-FOR-BIOMEDICAL-RESEARCH-INC 90% The October 2023 Amendment No. 1 expanded the size of the ongoing ribociclib and palazestrant study cohort to a total of approximately 60 patients.
AURIGENE AURIGENE 80% Payments due to Aurigene upon or subsequent to regulatory approval will be accrued as a provision to cost of sales in the period when achievement of respective milestone target is probable

Olema Pharmaceuticals, Inc. Customers

TickerNameConfidenceEvidence
AZN AstraZeneca PLC 72% of product candidates that we develop as viable treatment options; o addressing any competing technological and market developments; o negotiating favorable terms in any collaboration, licensing or o…
AZN AstraZeneca PLC 72% Reciprocal relationship from AZN graph: Reciprocal relationship from OLMA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from OLMA graph: Reciprocal relationship from AZN grap…
NVSEF Novartis AG 72% . In June 2025, the Company exercised its option to extend the lease term by an additional year, resulting in a revised expiration date of December 31, 2026 . The modification was accounted under ASC…
NVSEF Novartis AG 72% Reciprocal relationship from NVSEF graph: Reciprocal relationship from OLMA graph: . In June 2025, the Company exercised its option to extend the lease term by an additional year, resulting in a revi…
ALL-WALES-MEDICINES-STRATEGY-GROUP ALL-WALES-MEDICINES-STRATEGY-GROUP 62% eplace the expired ACA subsidies. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform me…
CAMBRIDGE-MASSACHUSETTS-OLEMA-ONCOLOGY-AUSTRALIA CAMBRIDGE-MASSACHUSETTS-OLEMA-ONCOLOGY-AUSTRALIA 62% complex since the information necessary to estimate the accruals is accumulated from the CROs and the Company's assessment of that information is subject to variability and uncertainty. In addition, …
COMPANY-LLC COMPANY-LLC 62% y is subject to risks and uncertainties common to late-stage companies in the biopharmaceutical industry, including, but not limited to, successful discovery and development of its product candidates…
DELAWARE-GENERAL-CORPORATION DELAWARE-GENERAL-CORPORATION 62% mplementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including: • increased operating expenses…
KR-OYSTER-POINT-II-LLC KR-OYSTER-POINT-II-LLC 62% . The modification was accounted under ASC 842, resulting in a remeasurement of the lease liability and a corresponding $ 0.1 million increase to the ROU asset. The incremental borrowing rate was als…
NOVARTIS-PHARMA-AG NOVARTIS-PHARMA-AG 62% . In June 2025, the Company exercised its option to extend the lease term by an additional year, resulting in a revised expiration date of December 31, 2026 . The modification was accounted under ASC…
NVS Novartis AG 62% Reciprocal relationship from NVS graph: Reciprocal relationship from OLMA graph: Reciprocal relationship from NVS graph: Reciprocal relationship from OLMA graph: Reciprocal relationship from NVS grap…
OLEMA-ONCOLOGY-AUSTRALIA-PTY-LTD OLEMA-ONCOLOGY-AUSTRALIA-PTY-LTD 62% ny is subject to risks and uncertainties common to late-stage companies in the biopharmaceutical industry, including, but not limited to, successful discovery and development of its product candidate…
PRESENTATION-OLEMA-PHARMACEUTICALS-INC PRESENTATION-OLEMA-PHARMACEUTICALS-INC 62% complex since the information necessary to estimate the accruals is accumulated from the CROs and the Company's assessment of that information is subject to variability and uncertainty. In addition, …
ROCHE-HOLDING-AG-GENENTECH-INC ROCHE-HOLDING-AG-GENENTECH-INC 62% of product candidates that we develop as viable treatment options; o addressing any competing technological and market developments; o negotiating favorable terms in any collaboration, licensing or o…
STEMLINE-THERAPEUTICS-INC STEMLINE-THERAPEUTICS-INC 62% of product candidates that we develop as viable treatment options; o addressing any competing technological and market developments; o negotiating favorable terms in any collaboration, licensing or o…
USA-LLC USA-LLC 62% nel-related costs, including an increase in non-cash stock-based compensation expense of $3.3 million mainly due to higher grant price in 2026, and higher headcount. General and administrative expens…

Olema Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
OLMA-DEBT Debt stack $4.0M 90% Market cache reports total debt of $4.0M.
OLMA-DEBT-11506 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.

Olema Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Olema Pharmaceuticals, Inc..

Olema Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
OLMA-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 202 tracked holders.

Olema Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
COLL Collegium Pharmaceutical, Inc. 100.00 2
HLNCF Haleon plc 100.00 2
ELVN Enliven Therapeutics, Inc. 100.00 2
ABT Abbott Laboratories 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
BNBX BNB Plus Corp. 100.00 2
ALLO Allogene Therapeutics, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
DEO Diageo plc 100.00 2
SDGR Schrödinger, Inc. 100.00 2
SLGL Sol-Gel Technologies Ltd. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 2
ALNY Alnylam Pharmaceuticals, Inc. 100.00 2
DRTS Alpha Tau Medical Ltd. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Olema Pharmaceuticals, Inc..

Unlock full OLMA data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
OLMA
Unlock OLMA Supply Chain Data
Verified relationships include:
KR-OYSTER-POINT-II-LLCKR-OYSTER-POINT-II-LLCSupplier92%
PFIZER-INCPFIZER-INCSupplier92%
AZNAstraZeneca PLCCustomer72%
AZNAstraZeneca PLCCustomer72%
+19 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →